



**HAL**  
open science

## Manufacturing antibodies in the plant cell

Diego Orzáez, Antonio Granell, Miguel A. Blázquez

► **To cite this version:**

Diego Orzáez, Antonio Granell, Miguel A. Blázquez. Manufacturing antibodies in the plant cell. Biotechnology Journal, 2009, 4 (12), pp.1712. 10.1002/biot.200900223 . hal-00546226

**HAL Id: hal-00546226**

**<https://hal.science/hal-00546226>**

Submitted on 14 Dec 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



## Manufacturing antibodies in the plant cell

Journal:	<i>Biotechnology Journal</i>
Manuscript ID:	biot.200900223.R1
Wiley - Manuscript type:	Review
Date Submitted by the Author:	24-Oct-2009
Complete List of Authors:	Orzáez, Diego; Instituto de Biología Molecular y Celular de Plantas (CSIC-UPV) Granell, Antonio; Instituto de Biología Molecular y Celular de Plantas (CSIC-UPV) Blázquez, Miguel; Universidad Politecnica de Valencia, Instituto de Biología Molecular y Celular de Plantas (UPV-CSIC)
Keywords:	Molecular farming, Plant-made antibodies, Plantibodies, sIgA, Agroinfiltration



view

1  
2  
3 Review ((9361 words))

Deleted: Title :

4 Manufacturing antibodies in the plant cell

5  
6  
7  
8 Diego Orzáez, Antonio Granell and Miguel A. Blázquez

Deleted: and

9  
10  
11 Instituto de Biología Molecular y Celular de Plantas (CSIC-UPV), Valencia, Spain.

12  
13  
14  
15  
16  
17  
18  
19  
20 **Keywords:**

21  
22 Molecular farming; Plant-made antibodies; Plantibodies; Glycosylation; Viral vectors;

23  
24 Agroinfiltration; sIgA; Unfolded Protein Response.

25  
26  
27  
28  
29  
30 **Correspondence:**

31  
32 Diego Orzáez

33  
34 Instituto de Biología Molecular y Celular de Plantas (CSIC-UPV)

35  
36 Ingeniero Fausto Elio s/n

37  
38 46022 Valencia

Deleted: 46021

39  
40 Spain

41  
42 Phone, +34 963 877 873

Deleted: xxx

43  
44 Fax, +34 963 877 859

45  
46 E-mail, dorzaez@ibmcp.upv.es

**Abbreviations:**

**BiP**, Immunoglobulin Heavy Chain Binding Protein; **CHO**, Chinese Hamster Ovary;

**CDR**, Complementarity-Determining Regions; **ER**, Endoplasmic Reticulum; **UPR**,

Unfolded Protein Response; **ERAD**, Endoplasmic Reticulum Associated Protein

Degradation; **TMV**, Tobacco Mosaic Virus; **TSP**, [Total Soluble Protein](#);

Deleted:

For Peer Review

**Abstract:**

Plants have long been considered advantageous platforms for large-scale production of antibodies due to their low cost, scalability, and the low chances of pathogen contamination. Much effort has therefore been devoted to efficiently produce mAbs (from nanobodies to secretory antibodies) in plant cells. Several technical difficulties have been encountered and are being coped with. Improvements in production levels have been achieved by manipulation of gene expression and, more efficiently, of cell targeting and protein folding and assembly. Differences in mAb glycosylation patterns between animal and plant cells are being successfully addressed by the elimination and introduction of the appropriate enzyme activities in plant cells. Another relevant battlefield is the dichotomy between production capacity and speed. Classically, stably transformed plant lines have been proposed for large scale mAb production, whereas the use of transient expression systems has always provided production speed at the cost of scalability. However, recent advances in transient expression techniques have brought impressive yield improvements, turning speed and scalability highly compatible assets. In the era of personalized medicines, the combination of yield and speed, and the advances in glyco-engineering have made the plant cell a serious contender in the field of recombinant antibody production.

Deleted: as

Deleted: MAb

Deleted: full-size antibodies to

Deleted: and

Deleted: cell targeting

Deleted: ,

Deleted: MAb

Deleted: dicotomy

Deleted: high

Deleted: Mab

## 1 Introduction

Recombinant gene technology is called to be one of the main ways to respond to the increasing manufacturing needs for novel molecular entities. Since the production of human insulin in *E. coli*, more than one hundred recombinant therapeutic drugs have been approved for commercialization and a tremendous amount of recombinant proteins are being used in diagnosis or research [1]. Fermentation in prokaryotes and yeast accounts for the majority of recombinant products; however, the increasing complexity of products is promoting the use of eukaryotes other than yeast as production systems. Such is the case of Chinese Hamster Ovary (CHO) cells, baculovirus-infected insect cells, and transgenic/transplactomic plants or plant cells. All these platforms have dramatically improved their performance in recent years, to cope with to the expected shortage of recombinant protein manufacturing capacity [2, 3]. For instance, the modifications introduced in prokaryotic systems have made them increasingly able to produce and display complex proteins [4], or have facilitated the introduction of whole metabolic pathways [5]; similarly, yeast strains have been engineered to display nearly-human glycosylation profiles [6]; CHO cells have multiplied their yields, reaching g/L levels [7]; alternative animal systems as chicken eggs have arisen [8], and baculovirus-based systems have been adapted to the production of multi-subunit protein complexes [9].

Monoclonal antibodies (mAbs) have attracted much of the effort in the field of recombinant protein technology. mAbs combine two types of bioactivities in the same molecule: the high binding specificity of their variable region, and the well-defined structure and effector functions of their constant regions. In addition, bioengineers have taken full advantage of this “natural” structure for the design of an array of antibody-

Field Code Changed

Deleted: the

Deleted: synthesized

Deleted: other

Deleted: , adapting

Field Code Changed

Deleted: [2]

Field Code Changed

Deleted: [3]

Field Code Changed

Deleted: [4]

Deleted: improved

Deleted: strains

Deleted: ing

Deleted: have been designed

Field Code Changed

Deleted: [5]

Field Code Changed

Deleted: [6]

Field Code Changed

Deleted: [7]

Field Code Changed

Deleted: [8]

Deleted: MAb

Deleted: s

Deleted: MAb

Deleted: s

1  
2 related structures. As a consequence, recombinant antibodies and their manmade  
3 derivatives have become a sort of magic bullet of modern biotechnology [10]. They are  
4 widely used as diagnostic reagents, both in health and research, but also more recently  
5 as therapeutic drugs, particularly for cancer treatments, where they have shown high  
6 efficacy [11].

7  
8  
9  
10  
11  
12 Human recombinant mAbs have entered the anti-tumor therapy mainstream through  
13 several technological waves. Initially, when just murine hybridoma technology was  
14 available the only mAbs were of mice origin. Therapeutic antibodies were then  
15 “humanized” by grafting the murine regions into human IgG constant frames.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

“Humanization” of murine mAbs was further improved by exchanging mouse scaffolds  
in the Complementarity-Determining Regions (CDR) for sequences of human origin.  
Finally, when phage display technology was developed for the screening of antibody-  
binding regions, human antibody libraries became available that allowed reconstitution  
of fully-human recombinant antibodies for therapy [11, 12].

Manufacturing technology was developing in parallel with display technologies.  
Initially there was not a definitive platform for the production of recombinant  
antibodies. Unlike single chain (scFv) antibody fragments, which could be produced as  
periplasmic proteins in bacterial fermentors, the more complex full-size recombinant  
antibodies required eukaryotic cells as biofactories. Plants, among others, were  
postulated from the beginning as a suitable production platform [13]. Transgenic plants’  
technology was however too slow and rudimentary to compete, and CHO cells finally  
became the standard for the antibody industry. To this date, all commercial therapeutic  
antibodies are produced in CHO cell fermentors. However monopoly of CHO cells is  
likely bound to end in the next few years, as laboratories and private companies demand  
new capabilities, such as speed, scalability and freedom to operate.

Deleted: -

Deleted: in

Deleted: [9]

Field Code Changed

Deleted: MAb

Deleted: only

Deleted: MAb

Deleted: MAb

Deleted: by

Deleted: as

Deleted: [9]

Field Code Changed

Deleted: [10]

Deleted: search

Deleted: for

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

It is not surprising that plants were initially envisaged by some as the most promising system for recombinant protein –and particularly antibody– production.

Plant-made antibodies offer several advantages, since they are (i) cheap, as plant cultivation guarantees low cost of goods; (ii) abundant, due to the enormous scaling up capacity of agronomical practices; and (iii) safe, since their evolutionary distance to humans reduces the chances of contamination with human pathogens (e.g. retrovirus, prions) (see also [\[14-17\]](#) for recent reviews on this issue)

Here we review the recent advances that have revitalized the field of plant-made antibody production, focusing in those modifications –both in the antibody and in the plant– that might facilitate the manufacturing of mAbs in the plant cell.

Deleted: Indeed, plant crops produce most of the proteins for human consumption, and plant-made ribulose-1-5 biphosphate carboxylase (Rubisco) is the most abundant protein on Earth.

Deleted: scale

Deleted: [11-14]

Field Code Changed

Deleted: in plant-made antibody production

Deleted: ,

Deleted: in

Deleted: MAb

## 2 Different formats for different purposes: from nanobodies to secretory IgA

Recombinant antibody-based molecular designs range from those most faithfully imitating nature, as IgG, to those aimed at maximum simplicity, as nanobodies, or those more complex or innovative designs, as immune-complexes or multivalent structures.

Each design, having its particular biosynthetic requirements (i.e. folding, secretion, glycosylation), may suit for certain production platforms and not others. Here we review those antibody formats that have been produced in plants and their adequacy to the plant production systems.

Deleted: most

Deleted: be

Deleted: ed

Deleted: for

### 2.1 Full size antibodies

Human IgG (Fig. 1) is probably the most wanted mAb isotype for plant production, because of its widespread use as an anti-tumor agent. In addition, downstream purification methods for IgG are well established and protein A affinity purification is a recognized safe standard for posterior therapeutic applications. Full size antibodies in

Deleted: MAb

1  
2 stably transformed plants are normally produced using dual gene constructs encoding  
3  
4 the heavy (H) and light (L) chains, each of them under the control of a promoter and a  
5  
6 transcriptional terminator. Human immunoglobulin native signal peptides are well  
7  
8 recognized in the plant cell, although certain authors prefer the use of plant native signal  
9  
10 peptides [18]. Both expression cassettes are often combined within the same binary  
11  
12 vector frame (also referred to as “co-transformation in cis”). The goal is to provide  
13  
14 coordinated expression of both antibody chains, which has been often considered a pre-  
15  
16 requisite for stable IgG expression [19]. These complex constructs are often difficult to  
17  
18 engineer, extending the antibody development process. Alternative methods are  
19  
20 “sequential co-transformation”, using different selection markers, and “co-  
21  
22 transformation in trans”, with H and L chains (and any additional polypeptide) inserted  
23  
24 in different expression cassettes and transformed simultaneously using a single selection  
25  
26 marker. This latter approach has been reported for cereals in combination with biolistics  
27  
28 [20], yielding high levels of co-transformation. The use of biolistics facilitates construct  
29  
30 manipulation due to the elimination of the requirement for large binary vectors used in  
31  
32 *Agrobacterium*-based transformation. In consequence, the development phase for  
33  
34 recombinant mAb production is accelerated. Nevertheless, from the pionner work of  
35  
36 Hiatt et al [13], to the most recent production of anti-HIV prophylactic IgG in corn [21,  
37  
38 22], the lengthy process of establishing a homozygous transgenic plant line with stable  
39  
40 and homogeneous IgG production has been the Achilles’ heel of plant-made antibodies.  
41  
42 More recently, the use of transient expression systems has contributed to ease these  
43  
44 limitations, paying a toll in scalability. The use of transient expression systems for IgG  
45  
46 production will be discussed in the section below.  
47  
48  
49  
50

## 51 2.2 Antibody fragments

52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted:

Deleted:

Deleted: [18]

Field Code Changed

Field Code Changed

Deleted: [19]

Deleted: where

Deleted: are

Field Code Changed

Deleted: [20]

Formatted: Font: Italic

Deleted: MAb

Field Code Changed

Deleted: [10]

Field Code Changed

Deleted: [21, 22]

Deleted: chapter

The observation that H chains retain some antigen-binding capacity even in the absence of L chains led to attempts to develop an even smaller antigen-binding unit in a miniaturized format. The smallest format found to keep full binding activity was the so-called single-chain fragment (scFv), in which the two variable regions, VH and VL, are artificially linked by a flexible polypeptide (Fig. 1). There are several examples in the literature showing scFv expression in different plant species (tobacco, tomato, pea) and plant organs (leaves, fruits, seeds) [14]. The reported production levels are also highly variable: in general scFvs are better expressed as ER-retained proteins, from almost undetectable levels to up to 6% TSP [23].

By serendipity, it was discovered that part of the humoral immune response of camels and llamas is based largely on H-chain antibodies where the L chain is missing. These unique antibody isotypes interact with the antigen through a single variable domain, referred to as VHH [24] (Fig. 1). Single domain antibodies have been produced in plants for immunomodulation of enzyme activity [25]. Plants may also be used as production platforms of single domain antibodies, although in certain circumstances VHHs may result toxic when produced in leaves at high levels (Orzaez et al, unpublished results).

It has to be kept in mind that scFv and VHH do not require glycosylation and can be assembled in prokaryotic systems like *E. coli* fermentors, which constitute therefore a strong competitor for plants. For the same reason, transplastomic plants are also suitable for the production of recombinant antibody fragments [17].

In the production of miniaturized antibodies, plants offer selective advantages compared to other platforms: the almost unlimited scaling up capacity and their use for food and animal feed makes plants an ideal platform for the development of veterinary vaccines [26]. This was the case for the pea seed production platform for anti-

**Deleted:** The observation that H chains retain some antigen-binding capacity in the absence of L chains led to attempts to obtain an even smaller antigen-binding unit in a VH format (Figure 1). However, several engineering efforts had to be made to overcome the reduced affinity for the antigen. As a result, scFvs were generated, in which the two variable regions, VH and VL, are artificially linked by a flexible polypeptide (Fig. 1).

**Field Code Changed**

**Deleted:** [11]

**Field Code Changed**

**Deleted:** [23]

**Field Code Changed**

**Deleted:** [24]

**Field Code Changed**

**Deleted:** [25]

**Field Code Changed**

**Deleted:** [14]

**Deleted:** a

**Deleted:** against

**Deleted:** ir

**Deleted:** , which

**Deleted:** made

**Deleted:** them

**Field Code Changed**

**Deleted:** [26]

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

coccidiosis antibody fragments once pursued by german-based company NovoPlant as a prophylactic device agent against chicken coccidiosis [27, 28]. This and similar approaches may still be considered as highly convenient once the negative European public perception on biofarming eases its halt in the development of local companies specialized in antibody production.

Deleted: [27]

Deleted: a

Deleted: for

### 2.3 Innovative antibody-based structures

A number of plant-made antibody-based structures has been proposed for improving stability, downstream processing or immune functions. Taking advantage of the stability conferred by IgG constant regions during expression in plants, chimeric molecules containing an antigenic (HIV-1 p24) region fused to C $\gamma$ 1-2 regions of IgG H chain have been shown to stabilize antigen production [29]. In another example, antibody fusion with elastin like proteins was shown to increase anti-HIV mAb yields and to facilitate downstream processing, without affecting neither their properties nor their glycosylation patterns [30, 31]. Particularly challenging structures for plant expression are recombinant immune complexes [32], which consist of complex arrangements where a certain antibody is fused against its own antigen creating a structure with potential immunomodulating activity. It is foreseeable that, as we learn more about immunological concepts like adjuvancy, immunomodulation and tolerance, newly designed antibody-based molecular structures with improved biological activity are likely to appear that will require a suitable platform (i.e plants) for large scale production.

Deleted: have

Field Code Changed

Deleted: [28]

Deleted: 2F5

Deleted: MAb

Deleted: neither its

Deleted: biochemical

Deleted: its

Field Code Changed

Deleted: [29]

Field Code Changed

Deleted: [30]

Deleted: in

Deleted: on

### 2.4 Secretory antibodies

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

A particularly interesting antibody isotype for plant-based production is the secretory immunoglobulin A (sIgA). In mammals, sIgA is the most important antibody isotype for mucosal protection. SIgA is formed in two stages (Fig. 2): First, B-lymphocytes produce dimeric IgA molecules in the lamina propria. Dimerization is regulated by the J-chain. Later, IgA dimers (dIgAs) bind to the polymeric immunoglobulin receptor (pIgR) at the basolateral surface of mucosal epithelium cells and are subsequently transcytosed to the intestinal lumen. Here the extracellular portion of pIgR, known as secretory component (SC), is proteolytically cleaved and remains attached to the IgA polymer rendering the heteromultimeric structure known as sIgA. This antibody isotype constitutes a highly stable complex that covers mucosal surfaces, acting as a first barrier against infection [33].

Deleted: ecretory

Deleted: . Secretory IgA (sI

Deleted: gA)

Field Code Changed

Deleted: [31]

Bulk production of sIgA for passive immunotherapy requires efficient, low cost manufacturing systems. Ma and co-workers demonstrated that plant cells can assemble mammalian antibodies in a secretory form: tobacco plants transformed with all four genes encoding chimeric sIgA/G produced fully functional secretory antibodies [34].

Field Code Changed

Deleted: [32]

The secretory version of this antibody accumulated at high levels in the plant, retained specificity against *Streptococcus mutans*, and conferred protection against dental caries

Field Code Changed

Deleted: [33]

Deleted: that

[35]. In fact, a milestone for plant molecular farming was the first EU approval for the commercialization of a plant-made recombinant product, which was awarded to California based company Planet-Biotech for the production of sIgG/A as a medical device for human health. Human sIgA has also been assembled in rice and corn

Deleted: also

Field Code Changed

Deleted: [20, 34]

Field Code Changed

Deleted: [35]

Deleted: SIgA

endosperm [20, 36] and recombinant bird sIgA complexes against *Eimeria* have been transiently assembled in tobacco plants [37]. sIgA has a great potential as a prophylactic molecule for the protection against pathogens that infect mucosal surfaces. In this sense, edible plant organs seem specially suited for recombinant sIgAs: they can be produced

in large amounts as required for passive prophylactic agents; moreover, partially purified, mucosal compatible plant-derived formulations containing sIgA could become an affordable vehicle for treatment and/or prevention of infection in oral or topical routes [38].

Deleted: the

Deleted: as

Deleted: the

Field Code Changed

Deleted: [36]

Deleted: Inspired by nature: mammalian cells producing antibodies

Deleted: MAb

Deleted: lymphocytes and

### 3. Potential molecular targets for the activation of antibody production in the plant cell

How to make a plant cell resemble a lymphocyte in terms of antibody production is a challenging biotechnology work. A close look at how mAbs are made in natural mAb biofactories, the mammalian plasma cells, can give clues on how to improve current technology in plants.

Deleted: In their natural biofactories, the lymphocytes, antibodies are synthesized through the cell endomembrane system. Antibody synthesis requires coordinated expression, folding and assembly of H and L chains. First, the corresponding mRNAs are matured and translated in the rough ER; then their nascent polypeptides are translocated into the ER and the N-terminal signal peptide is subsequently cleaved; folding is assisted by ER resident chaperones as the Immunoglobulin Heavy Chain Binding Protein (BiP) [37]. Besides, the Endoplasmic Reticulum Associated Protein Degradation (ERAD) quality control mechanism ensures that unfolded antibody chains are removed from the ER and degraded via the proteasome [38]. Finally, antibody chains are linked together by disulfide bonds established by ER-resident protein disulfide isomerase (PDI) [39]. ¶ In artificial systems such as CHO cells, several genetic strategies have been followed to increase MAb production. This includes engineering of anti-apoptotic factors to inhibit cell death in high density cultures, an approach that can be directly translated to plant cell suspension systems but possibly not to transgenic plants. A second obvious strategy consists in increasing gene expression by different means, like raising recombinant gene copy number, using more active promoters or targeting recombinant DNA to active transcriptional sites. These approaches, which do have a clear parallel in plants, have been only partially successful. It is generally accepted that MAb yield is not always a reflection of the abun...

Lymphocytes differentiate into plasma cells upon co-activation by antigen and helper T-cells. The hallmarks of this differentiation are a cell division arrest, size increase and the expansion of the endomembrane system that ensures high levels of protein secretion. In agreement with the expansion of the secretion machinery, differentiating plasma cells up-regulate their levels of ER chaperones and other ER-resident enzymes as BiP and Disulfide Isomerase. This phenomenon resembles the Unfolded Protein Response (UPR), a conserved mechanism activated in response to ER stress [39]. In the current model for UPR, three proteins act as proximal transducers: the Inositol-Requiring Enzyme 1 (IRE1), the Activating Transcription Factor 6 (ATF6) and the Protein kinase-like Endoplasmic Reticulum Kinase (PERK). All three elements are expressed constitutively and bound to BiP in basal conditions. Their release from BiP, either due to stress or as a response of a developmental program, unleashes a transcriptional response mediated by the X-box Binding Protein 1 (XBP1) transcription

Deleted: 1

Field Code Changed

Deleted: [41]

factor that results in [the](#) activation of several chaperones, but also apoptosis if certain injury threshold is reached [\[40\]](#).

Field Code Changed

Deleted: [42]

The understanding of the molecular mechanisms for plasma cell differentiation has opened the way for the rational engineering of artificial cells through the genetic up-regulation of a complete pathway instead of discrete genes. This was recently accomplished by overexpression of truncated version of XBP1 in CHO cells, which successfully induced a constitutive UPR that turned out in a significant increase in [mAb](#) production [\[41\]](#).

Deleted: MAb

Field Code Changed

Deleted: [43]

Deleted: ¶

Is there a lesson to be learned from plasma cell differentiation in plant-made antibodies? Could plant [mAb](#) production be enhanced by activation of UPR? A closer look [at the way the plant cell endomembrane system copes with an increase in the](#) demands for protein secretion could give some clues on how this could be accomplished.

Deleted: 4 Potential molecular targets for the activation of secretory pathway in the plant cell¶

Deleted: MAb

Deleted: to

Deleted: that

There are at least two circumstances in which plant cells activate their endomembrane system in a way that resembles plasma cell differentiation: during seed development and in response to pathogen attack. In both situations plant cells activate a developmental program that is equivalent to the yeast and mammalian UPR, and can be experimentally induced by the treatment with ER-stress inducers such as tunicamycin, an inhibitor of N-[glycosylation](#) [\[42, 43\]](#).

Deleted: glycosilation

Field Code Changed

Deleted: [44, 45]

Deleted: a

During the establishment of Systemic Acquired Resistance (SAR) in response to pathogen attack, Pathogenesis Response (PR) proteins are produced and sent to the vacuole and apoplast in high amounts. NPR1, a well-known master regulator of SAR, has [also](#) been shown to control [the expression of protein secretory pathway genes](#) [\[44\]](#), unveiling an interesting link between SAR and plant UPR. Indeed a certain parallelism can be drawn between lymphocyte activation in the vertebrate immune system and the

Deleted: also

Field Code Changed

Deleted: [46]

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

activation of SAR in the plant immune system: in vertebrates, the presence of non-self peptides or pathogen antigens indirectly activates, with the concurrence of T-helper cells and cytokines, the differentiation of plasma cells and/or the activation of cytotoxic T cells, natural secretory factories of antibodies. In a similar fashion, plant cells which are distant from the site of infection undergo the activation of a defense response by diffusible compounds like salicylic acid.

Deleted:

Once the link between UPR and SAR is established, it is interesting to look for plant regulators of UPR as potential candidates for activating the secretory pathway in plants.

Deleted: plants,

IRE1 homologues have been identified in plants; however their involvement in plant UPR has not been established. Although plants lack clear orthologues of XBP1 or

Deleted: nd a

ATF6, the promoters of ER chaperones, such as BiP, do contain regulatory elements

Formatted: Font: Italic

responsible for ER-stress response. In *Arabidopsis*, at least two bZIP transcription

Deleted: have been

factors, bZIP60 and bZIP28, were found to regulate ER-stress [45]. Interestingly,

Field Code Changed

bZIP60 is translocated to the nucleus in a truncated form, similar to the activation

Deleted: [47]

mechanism of mammalian ATF6 [46]. In agreement with a model that unifies ER-stress

Deleted: c

response and developmentally activated secretion, the cleaved form of bZIP60 was seen

Field Code Changed

to accumulate in anther tapetal cells, which are known to secrete large amounts of

Deleted: [48]

proteins and lipids and whose ER is hypertrophied, as observed in ultrastructural

Deleted: pollen

analysis. These results suggest that bZIP60 and bZIP28 could be potential candidates

for manipulating secretory functions in plant cells.

Deleted: mimic

The second physiological situation under which plant cells resembles plasma cell

differentiation is during seed development. In this case, plant cells activate storage

protein production in ER-derived protein bodies or protein storage vacuoles. Among

other changes, the preparation for active protein production includes an up-regulation of

BiP and other chaperones. This activation of the ER may be interpreted as a

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

developmentally-programmed event rather than a stress response triggered by cargo proteins, since it precedes the actual up-regulation of storage proteins. In maize, the activation of storage protein biosynthesis during seed development is activated by opaque-2, also a bZIP transcription factor. Opaque-2 binds the promoter region of storage zein genes, and up-regulates a number of enzymes involved in nitrogen and carbon metabolism, favoring the new role of endosperm cells as “biofactory” [47, 48].

Field Code Changed

Deleted: [49,50]

Deleted: MAb

The influence of [mAb](#) production upon the plant endomembrane system has not been studied in detail. Nevertheless, all the observations indicate that plant-made antibodies recruit plant chaperones in an analogous way as they do in animal cells. The presence of immunoglobulin chains in plants is associated with an increase in BiP and PDI expression, and plant BiP has been shown to mediate folding of IgG. BiP binds preferentially unfolded H chains which are then displaced by the presence of L chains [49]. These indications suggest that the activation of the secretory functions in the plant biofactories could positively influence [mAb](#) production. However the experience obtained from mammalian systems anticipates the requirement for coordinated upregulation of all downstream processing events including folding and assembly steps. Besides, it may not be such a straightforward strategy: while BiP overexpression seems to help to cope with drought stress in soybean [50], it has been reported to have detrimental effects [on](#) the accumulation of a recombinant T-cell pollen allergen in rice [51]. A more systemic approach for the activation of plant secretion, perhaps involving regulatory elements shared with plant UPR may help in boosting antibody production.

Field Code Changed

Deleted: [51]

Deleted: MAb

Deleted: [52]

Field Code Changed

Deleted: i

Field Code Changed

Deleted: [53]

## 5 Two edges sword: delivery versus disposal

Although extracellular secretion is the “natural” route for antibody production, it is not unusual to see [mAbs accumulating](#) in intracellular compartments [such us](#) the vacuole or

Deleted: MAb

Deleted: accumulate

Deleted: as

1  
2  
3 the ER. Interestingly, these are the compartments naturally used by plants cells (e.g.  
4 seed endosperm) to store proteins in the form of ER-derived protein bodies (PBs) and  
5 protein storage vacuoles (PSV). This rises the possibility to engineer these  
6 compartments as final destinations for plant-made mAbs. An interesting insight on this  
7 direction was provided by comparing the accumulation in tobacco leaves of anti-carries  
8  
9  
10  
11  
12 Guy's 13 antibody in two isotypes: IgG and a sIgG/A hybrid form. Murine IgG  
13 antibody, which was expressed in tobacco leaves at reasonable 1% TSP levels was  
14 efficiently secreted to the apoplast. Surprisingly, sIgA/G complex accumulated at levels  
15 up to 8% TSP. Although the differences in accumulation levels were initially attributed  
16 to the stability provided by SC, it was later observed that it was the accumulation in the  
17 vacuole and ER rather than the apoplast what could account in part for the higher level  
18 of sIgG/A production. Mistargeting to the vacuole was found to be provoked by a  
19 cryptic vacuolar sorting signal located at the tailpiece of IgG/A constant region [52, 53].  
20  
21 Thus, intracellular targeting and accumulation could be regarded as a potential  
22 mechanism to increase mAb productivity in plants. Unfortunately intracellular retention  
23 was accompanied by discrete degradation of IgG/A probably as a result of proteolytic  
24 activity in the vegetative (lytic) vacuole.  
25

Deleted: for protein storage

Deleted: The

Deleted: arises that these

Deleted: could be also  
engineered

Deleted: MAb

Deleted: issue

Deleted: [54, 55]

Deleted: intracellular

Deleted: r

Deleted:

Deleted: MAb

36 One of the peculiar characteristics of the plant secretory pathway is the presence of  
37 vacuoles, multipurpose organelles that often resemble the extracellular milieu in terms  
38 of protein trafficking. Recently, it has become established that targeting to the vacuole  
39 can follow two different routes. In the classical route, ER cargo is loaded to the Golgi  
40 apparatus and from there delivered into the vacuole in the presence of a vacuolar  
41 targeting signal. This classical route is followed by many hydrolases delivered to the  
42 lytic vacuole, as well as by seed storage proteins delivered to PSVs. Proteins following  
43 this route are decorated with complex glycans, a hallmark of their transit through the  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Golgi apparatus. It has been repeatedly observed, however, that many proteins, including recombinant antibodies engineered for secretion, ended up accumulating in the vacuole without the characteristic [glycosylation](#) patterns of the Golgi apparatus.

Deleted: glycosilation

This observation suggests the existence of an alternative shortcut to the classical route

Field Code Changed

[\[54\]](#). The determinants for secretion or vacuolar delivery are not yet fully understood,

Deleted: [56]

but the direct route from ER to the lytic vacuole may represent in some cases a sort of quality control mechanism for the disposal of improperly folded proteins. An extreme

example [of](#) how complicated the subcellular delivery of a recombinant antibody may be

Deleted: on

is provided by the detailed localization studies of sIgA produced in rice endosperm.

Here, subcellular targeting turned out to be dependent on the folded status of the

polypeptides, with non-assembled chains, accumulating within ER-derived protein

Deleted: ,

bodies, while the assembled antibody, accumulated specifically in protein storage

Deleted: ,

vacuoles [\[20\]](#).

Deleted: ,

Field Code Changed

Deleted: [20]

This and similar results raise the possibility of designing specific targeting to subcellular compartments, namely vacuole or ER-derived bodies, for the accumulation

of recombinant [mAbs](#), [following the path of](#) seed storage proteins [\[55\]](#). Retention in the

Deleted: MAb

Deleted: in a similar fashion as

ER can be easily induced by adding retention signals KDEL or HDEL. In fact, ER-

retention has been repeatedly reported to enhance accumulation of recombinant

antibodies in plants, most especially in the case of antibody fragments highly dependent

on disulfide bridges for proper folding [\[56\]](#). For certain proteins, ER milieu seems to

provide a certain degree of stability, which is lost once the protein is delivered to the

Golgi apparatus towards secretion. Another often claimed advantage of [mAb](#) retention

Deleted: MAb

in the ER is the absence [of](#) Golgi-derived complex glycosylation that could potentially

Deleted: in

cause immunogenicity in target organisms. [mAbs](#) free of complex glycans can be also

Deleted: MAb

[targeted](#) to the vacuole by engineering cleavable membrane anchored fusions to integral

Deleted: be

1  
2 proteins present in the Golgi-independent pathway to the vacuole, as recently [proposed](#)  
3  
4 [\[57\]](#).

Deleted: proposed

Field Code Changed

Deleted: [57]

## 6 Cut into pieces: stability, proteolysis and subcellular localization

10  
11 [Literature on plant-made mAb](#) is loaded with successful stories that may lead to the  
12 conclusion that all antibodies are well expressed in plants. However this is probably an  
13 observational selection effect; it is common experience to find large differences in  
14 expression levels among different [mAbs](#) and, although not often reported, a number of  
15 difficult-to-express [mAbs](#) yield unexpectedly poor expression levels. These striking  
16 differences were often attributed to positional effects of the transgenes. However with  
17 the use of transient methodologies (that will be discussed below), where positional  
18 effects can be discarded, it has become evident that stability differences among [mAb](#) do  
19 exist. This effect is even more striking when antibody variable regions are imported  
20 from combinatorial libraries (e.g. phage display selection). In an experience where 10  
21 full-size chicken antibodies derived from phage display were transiently expressed in  
22 *N. benthamiana* leaves, only six of them showed detectable accumulation levels in  
23 western analysis [\[37\]](#). An explanation for this low success [rate](#) is that Ig variable  
24 domains selected by phage display (in contrast to hybridoma-selected lines) have never  
25 encountered ER-folding and quality control systems and may [therefore](#) be inadequately  
26 adapted to it. In mammalian cells, improperly folded Ig domains are retained longer in  
27 the ER bound to BiP, and are finally translocated to the cytoplasm by the ER-quality  
28 control mechanism (ERAD) and ultimately degraded via the proteasome. Plant ERAD-  
29 like systems are active in degrading misfolded proteins. Recently it [has been](#)  
30 demonstrated that allelic forms of barley MLO protein which differ in single amino-acid  
31 substitutions are specifically degraded via ERAD in a process [that](#) requires proteasome

Deleted: P

Deleted: MAb

Deleted: literature

Deleted: MAb

Deleted: MAb

Deleted: ,

Deleted: MAb

Field Code Changed

Deleted: [35]

Deleted: was

Deleted: which

1  
2 function [58]. Interestingly, this situation resembles that of variable antibody chains  
3  
4 where idiotype differences are often determined by a few amino-acid changes. Plant  
5  
6 ERAD-like mechanism is assumed to play a role in the degradation of improperly  
7  
8 folded antibody chains; however this remains to be experimentally established.  
9

Deleted: [58]

Field Code Changed

10  
11 Another often misreported problem is the presence of small antibody fragments,  
12  
13 probably, resulting from discrete proteolytic degradation of HC and LC. mAb fragments  
14  
15 are especially difficult to remove by affinity purification and may represent a mayor  
16  
17 drawback in the optimization process. Generation of antibody fragments smaller than  
18  
19 the intact molecule is a common observation in plant expression systems [19, 59, 60]. A  
20  
21 detailed analysis of the antibody fragments produced by a secreted IgG in a root  
22  
23 expression system showed that they were not caused by antibody degradation during  
24  
25 protein extraction. Two smaller fragments of 50- and 80-kDa were identified as the  
26  
27 products of protease activity in the apoplast, whereas two additional fragments of 120-  
28  
29 and 135-kDa were most likely the products of proteolytic degradation along the  
30  
31 secretory pathway outside the endoplasmic reticulum (ER); the carbohydrate residues of  
32  
33 the 135-kDa antibody suggested that this fragment was formed between the ER and  
34  
35 Golgi [61]. A deeper understanding of the plant protease activities responsible for  
36  
37 antibody degradation is needed to minimize the detrimental effect of proteolysis in plant  
38  
39 mAb production.

Deleted: the

Deleted: of

Deleted: MAb

Field Code Changed

Deleted: [19, 59, 60]

Deleted: of

Field Code Changed

Deleted: [61]

Deleted: MAb

40  
41 Another particularly interesting subcellular localization for plant molecular farming  
42  
43 is the plastid, particularly as a result of transplastomic approach due to their capacity to  
44  
45 produce high yields of recombinant proteins. However plastids, lacking endomembrane  
46  
47 system, are unable to synthesize fully assembled, glycosylated antibodies. In an attempt  
48  
49 to produce an antibody structure resembling full-size mAb in algae chloroplasts, a  
50  
51 single chain IgA-like molecule was engineered consisting of a complete human  $\alpha$ HC  
52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted: MAb

Deleted: in

1  
2 covalently linked to a human LC variable region. The chimeric single chain IgA was  
3  
4 adequately folded in [the](#) plastid and displayed IgA-like binding activity [\[62\]](#). However  
5  
6 it should be noted that in the absence of glycosylation such antibodies are unable to bind  
7  
8 Fc receptors and activate effector functions, [and this poses](#) a limitation in the range of  
9  
10 potential applications of plastid-derived antibodies.  
11

Deleted: [62]

Field Code Changed

Deleted: y fragments

## 12 **7 Antibody decoration: advances in plant glyco-engineering**

13  
14  
15  
16  
17 Antibodies are highly glycosylated in their constant regions. As much as variable  
18  
19 regions determine [mAb](#) binding activity, glycosylation of constant regions determine  
20  
21 many other important antibody features such as resistance to protease degradation, half  
22  
23 life in serum and, most importantly for [mAb](#)-based immunotherapy, effector's function  
24  
25 by binding Fc receptors. Plant-made antibodies are glycosylated following the basic  
26  
27 principles of the eukaryotic secretion machinery (Fig. 3). ER-translocated nascent  
28  
29 peptides are decorated in certain Asn residues with an oligosaccharide rich in mannose,  
30  
31 Later in the process, mannose rich oligosaccharides are trimmed by ER-resident  
32  
33 mannosidase and subsequently engaged by N-acetyl-glucosamine transferase, which  
34  
35 adds terminal N-acetylglucosamine residues forming a typical biantennary complex that  
36  
37 enters the early Golgi . [Up to this point](#), plant [glycosylation](#) does not differ from that in  
38  
39 animals. Differences however do occur when proteins enter the Golgi apparatus, where  
40  
41 the formation of complex N-glycans takes place. In humans, biantennary complexes are  
42  
43 specifically decorated with  $\alpha$  1-6 fucose,  $\beta$  1-4 galactose, and sialic acid. All three  
44  
45 residues are absent in plants, which instead decorate with  $\alpha$  1-3 fucose,  $\beta$  1-2 xylose,  
46  
47 and sometimes a terminal structure known as Lewis a ( $\beta$  (1,3)Gal[ $\alpha$ (1,4)Fuc]) (see [\[63-](#)  
48  
49 [65\]](#) for recent reviews on this issue).  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted: s

Deleted: MAb

Deleted: MAb

Deleted: residues

Deleted: T

Deleted: glycosilation

Field Code Changed

Deleted: [63-65]

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

It is arguable to what extent “humanization” of plant-made mAb glycosylation patterns is strictly necessary, or if this will depend on the intended application. The data of possible allergenicity of plant specific glycans is controversial. Although no glycan-specific antibodies were generated in mice when exposed to plant-derived antibodies [66], this effect can not be generalized as it seems to be species-specific [63, 64, 67]. As a precautionary principle, especially for recombinant antibodies indented for systemic use, the current tendency is to imitate human glycosylation in plants. To this end, a two-step design has been followed. The first one is the knock out of those plant enzymes adding plant-specific residues, namely  $\alpha$  1-3 fucosyl transferase (FT) and  $\beta$  1-2 xylosyl transferase (XT).  $\Delta$ FT/XT plants have been engineered either using null mutants or RNAi technology in several species as *Arabidopsis*, tobacco and *Lemna minor*. In this latter system, North Carolina-based company Biolex reported the production of homogenously glycosilated antibodies devoid of plant specific glycans [68]. Nevertheless, the presence of  $\beta$  1-4 galactose and specially syalic acid as terminal residues in animal glycosylation patterns strongly determines the half life of the antibody in the serum, and therefore the engineering of plants with human specific transferases is also a desirable step. First attempts to knock in  $\beta$  1-4 galactosyl transferase (GalT) were only partially successful as they rendered very heterogeneous decorations [69] [70], but the result was much better when GalT was targeted to the late Golgi. The crossing of GalT knocked in plants with  $\Delta$ FT/XT mutants generated a tobacco line with a humanized glycosylation pattern. These plants were used, in combination with Icon’s magnification system (see below), for the production of highly homogeneous humanized antibodies [71]. Interestingly, antibodies produced in  $\Delta$ FT/ $\Delta$ XT/GalT plants were more effective than their CHO-made counterparts in neutralizing HIV infection, apparently due to their homogeneous glycosylation pattern

Deleted: MAb

Deleted: are

Deleted: on

Deleted: , and apparently species-dependent.

Deleted: a

Deleted: (Chargelegue

Deleted: et al., 2000)

Deleted:

Deleted:

Deleted: [63, 66].

Deleted: antibody

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

Deleted: [67]

Field Code Changed

Deleted: so

Deleted: a second step on the design of glycol-humanized plants consisting on the knock in of the

Deleted: enzymes

Deleted: ,

Formatted: Font: Italic

Deleted: (ref)

Formatted: Font: Italic

Field Code Changed

Deleted: [68]

1  
2  
3 that resembles that of human circulating IgG. This provides an example of how the  
4 tuning of N-glycans in plants can in some cases improve the therapeutic value of [mAbs](#).

Deleted: MAb

6 The only human modification that remains to be achieved [in plants](#) is the addition of  
7 terminal sialic residues. However this requires the introduction of a whole metabolic  
8 pathway in plants to synthesize, activate, transport and translocate N-acetylneuraminic  
9 acid into the late Golgi. This has been already accomplished with baculovirus-[infected](#)  
10 [insect cells](#) [72], and, despite the technical difficulties, the first steps in this direction  
11 have been also taken in plants [73], a proof of the raising interest in the use of plants as  
12 antibody production platforms.

Field Code Changed

Deleted: [69]

Field Code Changed

Deleted: [70]

18  
19  
20  
21  
22 **8 Little and fast or [lots](#) and slow: transient versus stable transformation**  
23 **technologies**

Deleted: much

24 Scalability was traditionally considered a main advantage of plant platforms.

25  
26  
27 Unexpectedly, some of the most promising plant-based expression systems [currently](#)  
28 [propose speed](#) rather than scalability as their main advantage. Initially, transient  
29 expression technologies were based solely [on](#) recombinant viral vectors, which spread  
30 recombinant protein production as they infect the plant (see [74] for a review on viral  
31 expression [systems](#)). However, the relatively big size of the antibody chains imposes a  
32 handicap in viral replication and movement, and clonal exclusion precludes the co-  
33 infection in a single cell with two viral vectors containing heavy and light chains.

Deleted: presently

Deleted: in

Deleted: ref

Deleted:

Deleted: systems

34  
35  
36  
37  
38  
39  
40  
41  
42  
43 Particularly interesting was the work made with Tobacco Mosaic Virus (TMV) in Large  
44 Scale Biology Corporation (LSB). This company developed a rapid TMV-based  
45 expression system for the production of anti-idiotypic scFv antibodies against non-  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Hodgkin's lymphoma [75], LSB even successfully began clinical trials, but failed to

Field Code Changed

Deleted: [71]

1  
2 maintain itself in the market. In a certain way, LSC anticipated the current boom of  
3  
4 transient expression technologies in plants.

5  
6 Most current transient technologies are based on *Agrobacterium tumefaciens* and its  
7 high efficiency to transfer DNA to plant cells in leaf tissues, and other organs like roots  
8  
9 or fruits [76]. With this technique, *Agrobacterium* suspension cultures are infiltrated by  
10  
11 pressure into the intercellular space of leaf mesophyll, efficiently transferring its T-  
12  
13 DNA to the plant cell nucleus (a technique known as agroinfiltration). Recombinant  
14  
15 gene constructs are actively transcribed and translated in a temporal window that begins  
16  
17 approximately two days post-inoculation and ceases approximately 3-5 days later. It has  
18  
19 been shown that silencing suppressors may burst expression at its maximum and delay  
20  
21 the decline in expression, indicating that transient expression is being limited by  
22  
23 silencing rather than by T-DNA degradation [77]. One of the most attractive features of  
24  
25 agroinfiltration is that the efficiency of co-delivery is very high, allowing easy co-  
26  
27 transformation of H- and L-chain constructs for antibody production. Moreover,  
28  
29 transgene expression levels obtained by agroinfiltration are in the range of the best  
30  
31 stable transformed lines. This provides acceptable production levels that have become  
32  
33 the basis of some of the technology employed by companies as Canada-based Medicago  
34  
35 Inc [78].

36  
37  
38 A major breakthrough in transient technologies was developed by Icon Genetics  
39  
40 group and their magniffection technique. Magniffection takes the best of two worlds by  
41  
42 combining the amplification power of viral vectors with the highly contained co-  
43  
44 transformation efficiency of agroinfiltration. This methodology is based on a viral  
45  
46 replicon derived from TMV, which is devoid of the capsid protein gene and therefore  
47  
48 lacks its capacity to move systemically. The replicative unit was *deconstructed* in two  
49  
50 pieces, with one of them designed to harbor a gene of interest. Each viral segment,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted: based in

Deleted: ,

Deleted: also

Field Code Changed

Deleted: [72]

Deleted: top

Deleted: [73]

Field Code Changed

Field Code Changed

Deleted: [74]

Deleted: based in

Deleted: of

1  
2 which is flanked by a homologous recombination site, is inserted in a separate  
3  
4 expression cassette and introduced in a separate binary vector. Both vectors, together  
5  
6 with a third one containing a recombinase, are co-delivered into plant cells using  
7  
8 agroinfiltration. The above mentioned high co-transformation rate of this methodology  
9  
10 ensures that a number of cells will become transformed with all three constructs  
11  
12 simultaneously. In the event of triple co-transformation, recombinase activity ensures  
13  
14 that a complete viral replicon will be *reconstructed* within the cell. The reassembled  
15  
16 RNA unit contains, together with the gene of interest, a RNA-dependent-RNA-  
17  
18 polymerase, that ensures gene amplification, and a movement protein (MP), which  
19  
20 ensures cell-to-cell spreading of the replicon throughout the entire agroinfiltrated leaf  
21  
22 [\[79, 80\]](#). Since RNA viruses do not enter the nucleus in its natural life cycle, Icon's  
23  
24 vector was elegantly tailored for its artificial nucleus-to cytoplasm passage by addition  
25  
26 of introns and removal of cryptic splicing sites [\[81\]](#). As a result, its performance was  
27  
28 significantly improved reaching levels of up to 40% TSP for certain recombinant  
29  
30 proteins.

31  
32 Despite its impressive performance, Icon's magnification technology faced the same  
33  
34 problem as other viral systems for [mAb](#) production. Co-infection within a single cell of  
35  
36 viral replicons containing H and L chains is a rare event due to clonal exclusion. The  
37  
38 problem was solved by introducing a second, non-competing virus in the game. It was  
39  
40 known for long in plant virology that viral co-infection may occur provided that both  
41  
42 players do not compete for the same cell resources as is the case for Potato Virus X  
43  
44 (PVX) and TMV [\(Fig. 4\)](#). Using complementary vectors derived from these viruses, H  
45  
46 and L chains were successfully co-expressed in *N. benthamiana* leaves, reaching  
47  
48 commercially viable levels of up to 10% TSP [\[82\]](#). It is noteworthy that the cell  
49  
50 secretion machinery is apparently able to cope with this vast amount of newly  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted: [75,76]

Field Code Changed

Deleted: [77]

Field Code Changed

Deleted: MAb

Field Code Changed

Deleted: [78]

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

circulating cargo without collapsing, and it is tempting to speculate that UPR-like adaptations discussed above could be taking place in response to the presence of viral proteins in the cell. A profile of PR expression could indicate if a UPR-like reaction is helping the ER to cope with mAb cargo in maginfected leaves. Icon Genetics was acquired by Bayer Innovation and it is currently attempting to bring to the market the concept of personalized vaccines against non-Hodgkin's lymphoma once ventured by LSB.

Deleted: MAb

The use of transient methodologies is gaining pace and new and improved methodologies are continuously emerging. Recently, Sainsbury and Lomonosoff reported a strikingly simple methodology based on Cowpea Mosaic Virus (CPMV) [83, 84]. The system, which also makes use of *Agrobacterium* as shuttle system, achieves extremely high levels of protein production without viral replication. It is based on the ability of a mutated version of 5'UTR of CPMV RNA2 to drive high levels of transcription. The absence of viral replication excludes clonal exclusion allowing high levels of co-transformation and reaching IgG expression levels of 10% TSP with a very simplified method. This and other transient rapid methodologies will surely have a role to play in responding to the increasing needs for rapid, tailor-made recombinant proteins.

Deleted: based in

Field Code Changed

Deleted: [79, 80]

Deleted: also

Formatted: Font: Italic

Deleted: based in

## 9. Summary and perspectives

Formatted: Font: Bold

Formatted: Indent: First line: 0 pt

As plant biotechnology develops, the restrictions initially hampering the development of plant-made recombinant proteins are being eased. This has brought a renewed interest of companies and research groups in plant-made antibodies. Transgenic technology has improved during the last 20 years, with many more species being routinely transformed and simpler and more efficient methods in place [85, 86].

1  
2 Downstream processing of plant extracts, which was initially neglected by plant  
3 biotechnologists, and turned to be a nightmare for the commercialization of the so-  
4 called “plantibodies”, has been conveniently addressed by several companies, which  
5 have substantially improved and scaled up the purification protocols [87].

6  
7  
8  
9  
10 While some old concerns are gradually being addressed, new opportunities arise  
11 from previously unforeseen technologies. Transient expression protocols provide the  
12 required speed for many modern manufacturing processes, as those related to custom  
13 production for individualized therapies. The full “humanization” of plant glycosylation  
14 patterns is underway, and those steps accomplished so far have produced recombinant  
15 mAbs with superior neutralizing activities when compared with competing platforms  
16 [71, 88]. Finally, as plant recombinant products are gradually available, current  
17 restrictions in the regulatory framework may well be relaxed, opening new  
18 opportunities. Hopefully, this and other regulatory changes, like the recent clearance for  
19 commercialization of partially purified botanical mixtures [89], may pave the way for  
20 large scale production of cheap prophylactic products based on plant-made mAbs, one  
21 of the big promises of this technology.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

Formatted: Indent: First  
line: 0 pt

Deleted: 9

#### 40 10 Acknowledgements

41  
42 Financial support for this article was provided by grants BIO2008-03434 and BIO2007-  
43 60923.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 11 Figure Legends

Deleted: 10

Deleted:

**Figure 1. Antibody formats manufactured in the plant cell.** (A) Schematic representation of a typical human IgG antibody, showing constant heavy (CH1-3), constant light (CL), variable heavy (VH) and variable light (VL) domains. The structure of IgG-derived antibody fragments is also shown. (B) Representation of a camelid antibody comprising only heavy chains but full antigen binding capacity. (C) Comparison of full length antibody with different antibody fragments and fusions expressed in plants. ScFv: single chain antibody fragment; VHH: single chain camelid antibody (nanobody); scFv-Fc single chain full-size antibody proposed for plastid expression; scFv-elastin: single chain-elastin fusions.

**Figure 2. Natural biosynthesis of secretory IgA in mucosal surfaces.** Polymeric IgA (pIgA) (composed of IgA and J chain) is secreted by plasma cells at the basolateral surface of mucosal epithelium. The Poly-immunoglobulin receptor (pIgR) mediates the transcytosis of IgA throughout the epithelium cell. At the luminal side, pIgR is cleaved releasing pIgA bound to its extracellular portion, the Secretory Component (SC). The final molecular complex, composed of IgA, Jchain and SC is known as secretory IgA (sIgA).

**Figure 3. N-Glycosylation patterns in plants and animals.** Schematic representation of the formation of typical complex glycans in the Golgi apparatus of animals (upper panel) and plants (lower panel).

**Figure 4. Simplified scheme of magnifection for the production of full-size mAbs.**

(A) Each chain of the mAb is inserted in a different, compatible viral vector, to allow coinfection of plant cells. Both vectors have been engineered to prevent systemic infection. In this example, the TMV-derived vector expresses the RNA-dependent polymerase (Pol), the movement protein (MP) and the mAb heavy chain (HC) from an actin promoter; and the PVX-derived vector lacks the coat protein but contains the RNA-dependent polymerase (Pol) and the mAb light chain (LC) genes expressed from the 35S promoter. RB and LB are the T-DNA right and left borders, respectively. (B) *Nicotiana* plants are vacuum- -infiltrated with low-density *Agrobacterium* cultures harboring the TMV and PVX vectors, resulting in a high proportion of cells being co-infected with HC (blue) or LC (red)-expressing constructs. Expression of the TMV movement protein allows cell-to-cell movement of TMV and PVX RNAs, thus spreading the co-expression of LC and HC in the same leaf areas (depicted as purple sectors resuting from red and blue color mixes).

## 12 References

- [1] Walsh, G., Current Status of Biopharmaceuticals: Approved Products and Trends in Approvals, in *Modern Biopharmaceuticals: Design, Development and Optimization*, J. Knäblein, Editor. 2005, WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim.
- [2] Molowa, D., Mazanet, R., The state of biopharmaceutical manufacturing. *Biotechnol. Annu. Rev.* 2003, 9, 295-301.
- [3] Kamarck, M. E., Building biomanufacturing capacity--the chapter and verse. *Nat Biotechnol.* 2006, 24, (5), 503-5.
- [4] Mazor, Y., Van Blarcom, T., Mabry, R., Iverson, B. L. *et al.*, Isolation of engineered, full-length antibodies from libraries expressed in *Escherichia coli*. *Nat Biotechnol.* 2007, 25, (5), 563-5.
- [5] Menzella, H. G., Reid, R., Carney, J. R., Chandran, S. S. *et al.*, Combinatorial polyketide biosynthesis by de novo design and rearrangement of modular polyketide synthase genes. *Nat Biotechnol.* 2005, 23, (9), 1171-6.
- [6] Hamilton, S. R., Gerngross, T. U., Glycosylation engineering in yeast: the advent of fully humanized yeast. *Curr. Opin. Biotechnol.* 2007, 18, (5), 387-92.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- [7] Wurm, F. M., Production of recombinant protein therapeutics in cultivated mammalian cells. *Nat Biotechnol.* 2004, 22, (11), 1393-8.
- [8] Zhu, L., van de Lavoie, M. C., Albanese, J., Beenhouwer, D. O. *et al.*, Production of human monoclonal antibody in eggs of chimeric chickens. *Nat Biotechnol.* 2005, 23, (9), 1159-69.
- [9] Berger, I., Fitzgerald, D. J., Richmond, T. J., Baculovirus expression system for heterologous multiprotein complexes. *Nat. Biotechnol.* 2004, 22, (12), 1583-1587.
- [10] Ehrlich, P., Croonian Lecture: On Immunity with Special Reference to Cell Life. *Proc. R. Soc. Lond.* 1899, 66, 424-448; .
- [11] Dübel, S., Therapeutic Antibodies - From Past to Future, in *Handbook of Therapeutic Antibodies*, S. Dübel, Editor. 2007, Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim.
- [12] McCafferty, J., Griffiths, A. D., Winter, G., Chiswell, D. J., Phage antibodies: filamentous phage displaying antibody variable domains. *Nature.* 1990, 348, (6301), 552-4.
- [13] Hiatt, A., Cafferkey, R., Bowdish, K., Production of Antibodies in Transgenic Plants. *Nature.* 1989, 342, (6245), 76-78.
- [14] Stoger, E., Sack, M., Fischer, R., Christou, P., Plantibodies: applications, advantages and bottlenecks. *Curr. Opin. Biotechnol.* 2002, 13, 161-166.
- [15] Ma, J. K. C., Drake, P. M. W., Christou, P., The production of recombinant pharmaceutical proteins in plants. *Nat. Rev. Genet.* 2003, 4, (10), 794-805.
- [16] Schillberg, S., Fischer, R., Emans, N., 'Molecular farming' of antibodies in plants. *Naturwissenschaften.* 2003, 90, (4), 145-155.
- [17] Ko, K., Brodzik, R., Steplewski, Z., Production of antibodies in plants: approaches and perspectives. *Curr. Top. Microbiol. Immunol.* 2009, 332, 55-78.
- [18] Smith, M. D., Antibody production in plants. *Biotechnol. Adv.* 1996, 14, (3), 267-81.
- [19] van Engelen, F. A., Schouten, A., Molthoff, J. W., Roosien, J. *et al.*, Coordinate expression of antibody subunit genes yields high levels of functional antibodies in roots of transgenic tobacco. *Plant Mol Biol.* 1994, 26, (6), 1701-10.
- [20] Nicholson, L., Gonzalez-Melendi, P., van Dolleweerd, C., Tuck, H. *et al.*, A recombinant multimeric immunoglobulin expressed in rice shows assembly-dependent subcellular localization in endosperm cells. *Plant Biotechnol J.* 2005, 3, (1), 115-27.
- [21] Ramessar, K., Rademacher, T., Sack, M., Stadlmann, J. *et al.*, Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. *Proc Natl Acad Sci U S A.* 2008, 105, (10), 3727-32.
- [22] Rademacher, T., Sack, M., Arcalis, E., Stadlmann, J. *et al.*, Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. *Plant Biotechnol J.* 2008, 6, (2), 189-201.
- [23] Fiedler, U., Phillips, J., Artsaenko, O., Conrad, U., Optimization of scFv antibody production in transgenic plants. *Immunotechnology.* 1997, 3, (3), 205-16.
- [24] Muyldermans, S., Cambillau, C., Wyns, L., Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. *Trends Biochem. Sci.* 2001, 26, (4), 230-5.

- 1  
2  
3 [25] Jobling, S. A., Jarman, C., Teh, M. M., Holmberg, N. *et al.*, Immunomodulation  
4 of enzyme function in plants by single-domain antibody fragments. *Nat*  
5 *Biotechnol.* 2003, *21*, (1), 77-80.  
6 [26] Floss, D. M., Falkenburg, D., Conrad, U., Production of vaccines and  
7 therapeutic antibodies for veterinary applications in transgenic plants: an  
8 overview. *Transgenic Res.* 2007, *16*, (3), 315-32.  
9 [27] Jahn, D., Matros, A., Bakulina, A. Y., Tiedemann, J. *et al.*, Model structure of  
10 the immunodominant surface antigen of *Eimeria tenella* identified as a target for  
11 sporozoite-neutralizing monoclonal antibody. *Parasitol Res.* 2009, *105*, (3), 655-  
12 68.  
13 [28] Zimmermann, J., Saalbach, I., Jahn, D., Giersberg, M. *et al.*, Antibody  
14 expressing pea seeds as fodder for prevention of gastrointestinal parasitic  
15 infections in chickens. *BMC Biotechnol.* 2009, *9*, 79.  
16 [29] Obregon, P., Chargelegue, D., Drake, P. M., Prada, A. *et al.*, HIV-1 p24-  
17 immunoglobulin fusion molecule: a new strategy for plant-based protein  
18 production. *Plant Biotechnol J.* 2006, *4*, (2), 195-207.  
19 [30] Floss, D. M., Sack, M., Stadlmann, J., Rademacher, T. *et al.*, Biochemical and  
20 functional characterization of anti-HIV antibody-ELP fusion proteins from  
21 transgenic plants. *Plant Biotechnol J.* 2008, *6*, (4), 379-91.  
22 [31] Floss, D. M., Sack, M., Arcalis, E., Stadlmann, J. *et al.*, Influence of elastin-like  
23 peptide fusions on the quantity and quality of a tobacco-derived human  
24 immunodeficiency virus-neutralizing antibody. *Plant Biotechnol J.* 2009,  
25 [32] Chargelegue, D., Drake, P. M., Obregon, P., Prada, A. *et al.*, Highly  
26 immunogenic and protective recombinant vaccine candidate expressed in  
27 transgenic plants. *Infect. Immun.* 2005, *73*, (9), 5915-22.  
28 [33] Corthesy, B., Spertini, F., Secretory immunoglobulin A: From mucosal  
29 protection to vaccine development. *Biol. Chem.* 1999, *380*, (11), 1251-1262.  
30 [34] Ma, J. K., Hiatt, A., Hein, M., Vine, N. D. *et al.*, Generation and assembly of  
31 secretory antibodies in plants. *Science.* 1995, *268*, (5211), 716-9.  
32 [35] Ma, J. K. C., Hikmat, B. Y., Wycoff, K., Vine, N. D. *et al.*, Characterization of a  
33 recombinant plant monoclonal secretory antibody and preventive  
34 immunotherapy in humans. *Nature Medicine.* 1998, *4*, (5), 601-606.  
35 [36] Larrick, J. W., Yu, L., Naftzger, C., Jaiswal, S. *et al.*, Production of secretory  
36 IgA antibodies in plants. *Biomol. Eng.* 2001, *18*, (3), 87-94.  
37 [37] Wieland, W. H., Lammers, A., Schots, A., Orzaez, D. V., Plant expression of  
38 chicken secretory antibodies derived from combinatorial libraries. *J. Biotechnol.*  
39 2006, *122*, (3), 382-91.  
40 [38] Casadevall, A., Dadachova, E., Pirofski, L. A., Passive antibody therapy for  
41 infectious diseases. *Nat. Rev. Microbiol.* 2004, *2*, (9), 695-703.  
42 [39] Harding, H. P., Calfon, M., Urano, F., Novoa, I. *et al.*, Transcriptional and  
43 translational control in the Mammalian unfolded protein response. *Annu. Rev.*  
44 *Cell Dev. Biol.* 2002, *18*, 575-99.  
45 [40] Gass, J. N., Gunn, K. E., Sriburi, R., Brewer, J. W., Stressed-out B cells?  
46 Plasma-cell differentiation and the unfolded protein response. *Trends Immunol.*  
47 2004, *25*, (1), 17-24.  
48 [41] Becker, E., Florin, L., Pfizenmaier, K., Kaufmann, H., An XBP-1 dependent  
49 bottle-neck in production of IgG subtype antibodies in chemically defined  
50 serum-free Chinese hamster ovary (CHO) fed-batch processes. *J. Biotechnol.*  
51 2008, *135*, (2), 217-23.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- [42] Wang, S., Narendra, S., Fedoroff, N., Heterotrimeric G protein signaling in the Arabidopsis unfolded protein response. *Proc Natl Acad Sci U S A.* 2007, *104*, (10), 3817-22.
- [43] Vitale, A., Boston, R. S., Endoplasmic reticulum quality control and the unfolded protein response: insights from plants. *Traffic.* 2008, *9*, (10), 1581-8.
- [44] Wang, D., Weaver, N. D., Kesarwani, M., Dong, X., Induction of protein secretory pathway is required for systemic acquired resistance. *Science.* 2005, *308*, (5724), 1036-40.
- [45] Iwata, Y., Koizumi, N., An Arabidopsis transcription factor, AtbZIP60, regulates the endoplasmic reticulum stress response in a manner unique to plants. *Proc Natl Acad Sci U S A.* 2005, *102*, (14), 5280-5.
- [46] Iwata, Y., Fedoroff, N. V., Koizumi, N., Arabidopsis bZIP60 is a proteolysis-activated transcription factor involved in the endoplasmic reticulum stress response. *Plant Cell.* 2008, *20*, (11), 3107-21.
- [47] Schmidt, R. J., Ketudat, M., Aukerman, M. J., Hoschek, G., Opaque-2 is a transcriptional activator that recognizes a specific target site in 22-kD zein genes. *Plant Cell.* 1992, *4*, (6), 689-700.
- [48] Vitale, A., Ceriotti, A., Protein quality control mechanisms and protein storage in the endoplasmic reticulum. A conflict of interests? *Plant Physiol.* 2004, *136*, (3), 3420-6.
- [49] Nuttall, J., Vine, N., Hadlington, J. L., Drake, P. *et al.*, ER-resident chaperone interactions with recombinant antibodies in transgenic plants. *Eur. J. Biochem.* 2002, *269*, (24), 6042-6051.
- [50] Valente, M. A., Faria, J. A., Soares-Ramos, J. R., Reis, P. A. *et al.*, The ER luminal binding protein (BiP) mediates an increase in drought tolerance in soybean and delays drought-induced leaf senescence in soybean and tobacco. *J. Exp. Bot.* 2009, *60*, (2), 533-46.
- [51] Yasuda, H., Hirose, S., Kawakatsu, T., Wakasa, Y. *et al.*, Overexpression of BiP has inhibitory effects on the accumulation of seed storage proteins in endosperm cells of rice. *Plant Cell Physiol.* 2009, *50*, (8), 1532-43.
- [52] Hadlington, J. L., Santoro, A., Nuttall, J., Denecke, J. *et al.*, The C-terminal extension of a hybrid immunoglobulin A/G heavy chain is responsible for its golgi-mediated sorting to the vacuole. *Mol. Biol. Cell.* 2003, *14*, (6), 2592-2602.
- [53] Frigerio, L., Vine, N. D., Pedrazzini, E., Hein, M. B. *et al.*, Assembly, secretion, and vacuolar delivery of a hybrid immunoglobulin in plants. *Plant Physiol.* 2000, *123*, (4), 1483-1493.
- [54] Vitale, A., Galili, G., The endomembrane system and the problem of protein sorting. *Plant Physiol.* 2001, *125*, (1), 115-8.
- [55] Torrent, M., Llop-Tous, I., Ludevid, M. D., Protein body induction: a new tool to produce and recover recombinant proteins in plants. *Methods Mol. Biol.* 2009, *483*, 193-208.
- [56] Schouten, A., Roosien, J., van Engelen, F. A., de Jong, G. A. *et al.*, The C-terminal KDEL sequence increases the expression level of a single-chain antibody designed to be targeted to both the cytosol and the secretory pathway in transgenic tobacco. *Plant Mol Biol.* 1996, *30*, (4), 781-93.
- [57] Wang, J., Miao, Y., Jiang, L., Response to Gomord *et al.*: Golgi-bypassing: delivery of biopharmaceutical proteins to protein storage vacuoles in plant bioreactors. *Trends Biotechnol.* 2006, *24*, (4), 147-9.

- 1  
2  
3 [58] Muller, J., Piffanelli, P., Devoto, A., Miklis, M. *et al.*, Conserved ERAD-like  
4 quality control of a plant polytopic membrane protein. *Plant Cell*. 2005, 17, (1),  
5 149-63.  
6 [59] De Neve, M., De Loose, M., Jacobs, A., Van Houdt, H. *et al.*, Assembly of an  
7 antibody and its derived antibody fragment in *Nicotiana* and *Arabidopsis*.  
8 *Transgenic Res.* 1993, 2, (4), 227-37.  
9 [60] Khoudi, H., Laberge, S., Ferullo, J. M., Bazin, R. *et al.*, Production of a  
10 diagnostic monoclonal antibody in perennial alfalfa plants. *Biotechnol. Bioeng.*  
11 1999, 64, (2), 135-43.  
12 [61] Sharp, J. M., Doran, P. M., Characterization of monoclonal antibody fragments  
13 produced by plant cells. *Biotechnol. Bioeng.* 2001, 73, (5), 338-46.  
14 [62] Mayfield, S. P., Franklin, S. E., Lerner, R. A., Expression and assembly of a  
15 fully active antibody in algae. *Proc Natl Acad Sci U S A*. 2003, 100, (2), 438-42.  
16 [63] Ko, K., Ahn, M. H., Song, M., Choo, Y. K. *et al.*, Glyco-engineering of  
17 biotherapeutic proteins in plants. *Mol. Cells*. 2008, 25, (4), 494-503.  
18 [64] Saint-Jore-Dupas, C., Faye, L., Gomord, V., From planta to pharma with  
19 glycosylation in the toolbox. *Trends Biotechnol.* 2007, 25, (7), 317-23.  
20 [65] Gomord, V., Sourrouille, C., Fitchette, A. C., Bardor, M. *et al.*, Production and  
21 glycosylation of plant-made pharmaceuticals: the antibodies as a challenge.  
22 *Plant Biotechnol J.* 2004, 2, (2), 83-100.  
23 [66] Chargelegue, D., Vine, N. D., van Dolleweerd, C. J., Drake, P. M. *et al.*, A  
24 murine monoclonal antibody produced in transgenic plants with plant-specific  
25 glycans is not immunogenic in mice. *Transgenic Res.* 2000, 9, (3), 187-94.  
26 [67] Jin, C., Altmann, F., Strasser, R., Mach, L. *et al.*, A plant-derived human  
27 monoclonal antibody induces an anti-carbohydrate immune response in rabbits.  
28 *Glycobiology*. 2008, 18, (3), 235-41.  
29 [68] Cox, K. M., Sterling, J. D., Regan, J. T., Gasdaska, J. R. *et al.*, Glycan  
30 optimization of a human monoclonal antibody in the aquatic plant *Lemna minor*.  
31 *Nat Biotechnol.* 2006, 24, (12), 1591-7.  
32 [69] Palacpac, N. Q., Yoshida, S., Sakai, H., Kimura, Y. *et al.*, Stable expression of  
33 human beta1,4-galactosyltransferase in plant cells modifies N-linked  
34 glycosylation patterns. *Proc Natl Acad Sci U S A*. 1999, 96, (8), 4692-7.  
35 [70] Bakker, H., Bardor, M., Molthoff, J. W., Gomord, V. *et al.*, Galactose-extended  
36 glycans of antibodies produced by transgenic plants. *Proc Natl Acad Sci U S A*.  
37 2001, 98, (5), 2899-904.  
38 [71] Strasser, R., Castilho, A., Stadlmann, J., Kunert, R. *et al.*, Improved Virus  
39 Neutralization by Plant-produced Anti-HIV Antibodies with a Homogeneous  
40 {beta}1,4-Galactosylated N-Glycan Profile. *J. Biol. Chem.* 2009, 284, (31),  
41 20479-85.  
42 [72] Jarvis, D. L., Developing baculovirus-insect cell expression systems for  
43 humanized recombinant glycoprotein production. *Virology*. 2003, 310, (1), 1-7.  
44 [73] Paccalet, T., Bardor, M., Rihouey, C., Delmas, F. *et al.*, Engineering of a sialic  
45 acid synthesis pathway in transgenic plants by expression of bacterial Neu5Ac-  
46 synthesizing enzymes. *Plant Biotechnol J.* 2007, 5, (1), 16-25.  
47 [74] Lico, C., Chen, Q., Santi, L., Viral vectors for production of recombinant  
48 proteins in plants. *J Cell Physiol*. 2008, 216, (2), 366-77.  
49 [75] McCormick, A. A., Reinl, S. J., Cameron, T. I., Vojdani, F. *et al.*, Individualized  
50 human scFv vaccines produced in plants: humoral anti-idiotypic responses in  
51 vaccinated mice confirm relevance to the tumor Ig. *J. Immunol. Methods*. 2003,  
52 278, (1-2), 95-104.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- [76] Orzaez, D., Mirabel, S., Wieland, W. H., Granell, A., Agroinjection of tomato fruits. A tool for rapid functional analysis of transgenes directly in fruit. *Plant Physiol.* 2006, *140*, (1), 3-11.
- [77] Voinnet, O., Rivas, S., Mestre, P., Baulcombe, D., An enhanced transient expression system in plants based on suppression of gene silencing by the p19 protein of tomato bushy stunt virus. *Plant J.* 2003, *33*, (5), 949-956.
- [78] D'Aoust, M. A., Lavoie, P. O., Belles-Isles, J., Bechtold, N. *et al.*, Transient expression of antibodies in plants using syringe agroinfiltration. *Methods Mol. Biol.* 2009, *483*, 41-50.
- [79] Gleba, Y., Klimyuk, V., Marillonnet, S., Magniflection--a new platform for expressing recombinant vaccines in plants. *Vaccine.* 2005, *23*, (17-18), 2042-8.
- [80] Marillonnet, S., Giritch, A., Gils, M., Kandzia, R. *et al.*, In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by *Agrobacterium*. *Proc Natl Acad Sci U S A.* 2004, *101*, (18), 6852-7.
- [81] Marillonnet, S., Thoeringer, C., Kandzia, R., Klimyuk, V. *et al.*, Systemic *Agrobacterium tumefaciens*-mediated transfection of viral replicons for efficient transient expression in plants. *Nat. Biotechnol.* 2005, *23*, (6), 718-723.
- [82] Giritch, A., Marillonnet, S., Engler, C., van Eldik, G. *et al.*, Rapid high-yield expression of full-size IgG antibodies in plants coinfecting with noncompeting viral vectors. *Proc Natl Acad Sci U S A.* 2006, *103*, (40), 14701-6.
- [83] Sainsbury, F., Thuenemann, E. C., Lomonosoff, G. P., pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. *Plant Biotechnol J.* 2009, *7*, (7), 682-93.
- [84] Sainsbury, F., Lomonosoff, G. P., Extremely high-level and rapid transient protein production in plants without the use of viral replication. *Plant Physiol.* 2008, *148*, (3), 1212-8.
- [85] Zhu, C., Naqvi, S., Breitenbach, J., Sandmann, G. *et al.*, Combinatorial genetic transformation generates a library of metabolic phenotypes for the carotenoid pathway in maize. *Proc Natl Acad Sci U S A.* 2008, *105*, (47), 18232-7.
- [86] Shewry, P. R., Jones, H. D., Halford, N. G., Plant biotechnology: transgenic crops. *Adv. Biochem. Eng. Biotechnol.* 2008, *111*, 149-86.
- [87] Rybicki, E. P., Plant-produced vaccines: promise and reality. *Drug Discov. Today.* 2009, *14*, (1-2), 16-24.
- [88] Castilho, A., Pabst, M., Leonard, R., Veit, C. *et al.*, Construction of a functional CMP-sialic acid biosynthesis pathway in *Arabidopsis*. *Plant Physiol.* 2008, *147*, (1), 331-9.
- [89] Chen, S. T., Dou, J., Temple, R., Agarwal, R. *et al.*, New therapies from old medicines. *Nat Biotechnol.* 2008, *26*, (10), 1077-83.

Page 11: [1] Deleted dorzaez 10/21/2009 6:14:00 PM

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

In their natural biofactories, the lymphocytes, antibodies are synthesized through the cell endomembrane system. Antibody synthesis requires coordinated expression, folding and assembly of H and L chains. First, the corresponding mRNAs are matured and translated in the rough ER; then their nascent polypeptides are translocated into the ER and the N-terminal signal peptide is subsequently cleaved; folding is assisted by ER resident chaperones as the Immunoglobulin Heavy Chain Binding Protein (BiP) [37]. Besides, the Endoplasmic Reticulum Associated Protein Degradation (ERAD) quality control mechanism ensures that unfolded antibody chains are removed from the ER and degraded via the proteasome [38]. Finally, antibody chains are linked together by disulfide bonds established by ER-resident protein disulfide isomerase (PDI) [39].


In artificial systems such as CHO cells, several genetic strategies have been followed to increase MAb production. This includes engineering of anti-apoptotic factors to inhibit cell death in high density cultures, an approach that can be directly translated to plant cell suspension systems but possibly not to transgenic plants. A second obvious strategy consists in increasing gene expression by different means, like raising recombinant gene copy number, using more active promoters or targeting recombinant DNA to active transcriptional sites. These approaches, which do have a clear parallel in plants, have been only partially successful. It is generally accepted that MAb yield is not always a reflection of the abundance of its transcript in the cell. Instead, folding and assembly have been considered as major bottlenecks in antibody production. Consequently, the engineering of mammalian cells as artificial factories has often tried to remove folding and assembly bottlenecks, i.e. by upregulating discrete steps in the process, as PDI and BiP. However these discrete approaches have not been particularly successful. Protein

1  
2  
3 folding and assembly can be considered as a chain of potential bottlenecks, therefore it is  
4  
5 not surprising that removal of a single bottleneck will only marginally alleviate constraints  
6  
7 imposed in the system -reviewed by [40].  
8  
9


10 A more comprehensive approach recently undertaken to improve MAb production in  
11  
12 artificial mammalian systems relies in a better understanding of plasma cell  
13  
14 differentiation. Plasma cells are natural antibody factories:  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

